Erasca Narrows Loss 46% in Fiscal Q2
Erasca ( NASDAQ:ERAS ) , a clinical-stage biotechnology company focused on developing cancer therapies targeting the RAS/MAPK pathway, released its second quarter results on August 12, 2025. The company highlighted accelerated progress for two key clinical programs and reported operating expenses ...
Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will ...
Erasca to Present at the Bank of America Securities Health Care Conference
SAN DIEGO, May 07, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank ...
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - Erasca ( NASDAQ:ERAS )
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Beam Therapeutics ( NASDAQ:BEAM ) , B2Gold ( AMEX:BTG )
U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's session. Baird analyst Jonathan Komp upgraded the rating for Wolverine World Wide from Neutral to Outperform.
CITY HILL ARTS TO PRODUCE INCREDIBLE MEDICAL THRILLER "CHASING MY CURE" BASED ON LIFE OF DR. DAVID FAJGENBAUM
-Academy Award Winning Producer Wendy Finerman collaborates with Former Star Quarterback turned Pioneering Doctor and entrepreneur Jonathan E. Lim for inspirational Medical Drama- LOS ANGELES, April 17, 2025 /PRNewswire/ -- City Hill Arts, the film and media production and financing company ...
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Shake Shack ( NYSE:SHAK ) , Erasca ( NASDAQ:ERAS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ...
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - Erasca ( NASDAQ:ERAS )
SAN DIEGO, Jan. 31, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the ...
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca ( ERAS )
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
Down -27.17% in 4 Weeks, Here's Why Erasca ( ERAS ) Looks Ripe for a Turnaround
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca ( ERAS )
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca ( ERAS )
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session - BARK ( NYSE:BARK ) , Erasca ( NASDAQ:ERAS )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Stellantis N.V. STLA fell sharply in today's pre-market trading.
Erasca ( ERAS ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Erasca to Present at Upcoming Investor Conferences - Erasca ( NASDAQ:ERAS )
SAN DIEGO, Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- Erasca, Inc.
Should You Buy Erasca, Inc. ( ERAS ) After Golden Cross?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday - e.l.f. Beauty ( NYSE:ELF )
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. ELF rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter earnings. e.l.f.
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Erasca ( NASDAQ:ERAS )
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session - DXC Technology ( NYSE:DXC )
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday. Shares of DXC Technology Company DXC fell sharply in today's pre-market trading after the company issued weak guidance.
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors ...
Erasca Announces Pricing of Underwritten Offering of Common Stock
SAN DIEGO, May 16, 2024 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten ...
Soft Instrument Orders Likely to Hurt PacBio's ( PACB ) Q1 Earnings
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Here's How Cresco Labs ( CRLBF ) is Placed Before Q1 Earnings
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Should SNDL ( SNDL ) be in Your Portfolio Ahead of Q1 Earnings?
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
Should You Buy Hims & Hers Health ( HIMS ) Ahead of Q1 Earnings?
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Strength in Kidney Care Likely to Aid DaVita's ( DVA ) Q1 Earnings
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
Erasca ( ERAS ) Upgraded to Strong Buy: What Does It Mean for the Stock?
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for April 23rd
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
New Strong Buy Stocks for April 23rd
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
Erasca Announces $45 Million Oversubscribed Private Placement Financing - Erasca ( NASDAQ:ERAS )
SAN DIEGO, March 27, 2024 ( GLOBE NEWSWIRE ) -- Erasca, Inc.
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026 Funding from new and existing investors extends anticipated cash runway into ...
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - Erasca ( NASDAQ:ERAS )
SAN DIEGO, Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual ...
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying - CommScope Hldg Co ( NASDAQ:COMM ) , Erasca ( NASDAQ:ERAS )
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors ...
4 Penny Stocks To Watch Before Next Week With Big News
Penny stocks, defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in price. This extreme sensitivity makes them risky but also creates opportunities for short-term ...
3 Penny Stocks To Buy According To Insiders In December
Penny stocks - the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
$1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Aspira Womens Health ( NASDAQ:AWH ) , Charles & Colvard ( NASDAQ:CTHR )
The Dow Jones closed lower by around 70 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Eterna Therapeutics Inc. ( Nasdaq: ERNA ) ( "Eterna" or the "Company" ) , a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the ...
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday - Arista Networks ( NYSE:ANET ) , Ardelyx ( NASDAQ:ARDX )
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today's session. Verve Therapeutics, Inc. VERV gained 27% to $11.95.
Why Shares of Erasca Are Jumping Tuesday
The company's chairman and CEO bought more than $2.025 million worth of company stock.
2.03M Reasons To Be Bullish On Erasca Stock - Erasca ( NASDAQ:ERAS )
Jonathan Lim, Chairman & CEO at Erasca ERAS, reported a large insider buy on October 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Lim purchased 1,000,000 shares of Erasca. The total transaction amounted ...
Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe - Pfizer, Inc. Common Stock ( NYSE:PFE )
While Pfizer Inc PFE and Moderna Inc MRNA are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated.
Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock ( NYSE:BMY ) , SenesTech, Inc. - Common Stock ( NASDAQ:SNES )
On Wednesday, 311 stocks hit new 52-week lows. Bristol-Myers Squibb Company Common Stock BMY is the largest company in terms of market cap to set a new 52-week low this morning. SenesTech, Inc. - Common Stock SNES was the smallest company by market cap to set a new 52-week low. A10 Networks, ...
